MARC details
000 -LEADER |
fixed length control field |
02040nam a22002417a 4500 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
ISI Library, Kolkata |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240903140617.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
240827b |||||||| |||| 00| 0 eng d |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
ISI Library |
Language of cataloging |
English |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Edition number |
23rd |
Classification number |
100 SD:610.621 |
Item number |
WHO.TR.693 |
110 1# - MAIN ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
WHO scientific grop on viral vaccines and antiviral drugs |
Relator term |
Corporate author |
245 10 - TITLE STATEMENT |
Title |
Viral vaccines and antiviral drugs: |
Remainder of title |
report of a WHO scientific group/ |
Statement of responsibility, etc |
WHO scientific group on viral vaccines and antiviral drugs |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
Place of publication, distribution, etc |
Geneva: |
Name of publisher, distributor, etc |
World health organization, |
Date of publication, distribution, etc |
1983. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
72 pages; |
Other physical details |
diagrams; |
Dimensions |
19 cm. |
490 0# - SERIES STATEMENT |
Series statement |
Technical Report Series; |
Volume number/sequential designation |
693 |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc |
Includes bibliography |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
1. Introduction -- 2. Antiviral immune responses -- 3. New approaches to vaccine development -- 4. Developments in interferons and antiviral compounds -- 5. Consideration of specific viral diseases -- 6. Recommendations |
520 ## - SUMMARY, ETC. |
Summary, etc |
In order that the new technologies are harnessed for the maximum benefit of all countries, it is essential that WHO should coordinate the efforts of scientists and others involved in research and development work in this field. Careful consideration should be given to clinical studies of new vaccines and drugs and to their standardization and control. During the past decade, communicable diseases have continued to have a considerable impact on morbidity and mortality, often resulting in an insupportable burden on national health resources. In many areas, viral infections account for a major proportion of the total incidence of communicable disease and, moreover, are often accompanied by secondary bacterial infections. In some countries, effective prevention and control of certain viral diseases, such as measles and poliomyelitis, is adequate using the vaccines currently available. Nevertheless, improvements in the prevention and control |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Biological Science |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Vaccines and antiviral drugs |
710 1# - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
World health organization (WHO) |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
Dewey Decimal Classification |
Koha item type |
Reports |